Vanguard Fiduciary Trust
CYTK icon

Vanguard Fiduciary Trust’s Cytokinetics CYTK Stock Holding History

Vanguard Fiduciary Trust’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$77.2M Buy
906,423
+106,801
+13% +$7.67M 0.02% 650
2026
Q1 		$52.7M Buy
+799,622
New +$50.8M 0.01% 765

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust's CYTK Position: Q2 2026 in Review

Vanguard Fiduciary Trust increased its Cytokinetics (CYTK) stake by 13% in Q2 2026, buying an estimated $7.67M and bringing the position to 906,423 shares worth $77.2M. The position accounts for 0.02% of the portfolio, ranked #650.

Vanguard Fiduciary Trust first reported a position in CYTK in Q1 2026 and has held it in 2 quarters since. 479 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Vanguard Fiduciary Trust held 906,423 shares of Cytokinetics worth $77.2M as of Q2 2026.
  • Vanguard Fiduciary Trust bought 106,801 Cytokinetics shares in Q2 2026, an estimated $7.67M.
  • Cytokinetics made up 0.02% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #650 holding.
  • Vanguard Fiduciary Trust first reported a position in Cytokinetics in Q1 2026 and has held it in 2 quarters since.
  • 479 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.